Everything below concerns GHRH analogue. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-07-21. Where a claim depends on a specific study, the study is described rather than over-claimed.
Tesamorelin acts on the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in intracellular cyclic AMP, which in turn opens ion channels and raises calcium concentrations, leading to release of stored growth hormone into the bloodstream. Because the peptide works through the same receptor as the body's own GHRH, the resulting secretion follows a pulsatile pattern rather than a continuous elevation. The N-terminal modification slows enzymatic breakdown, so the signal persists longer than it would with the unmodified hormone.
Growth hormone released from the pituitary stimulates the liver and other tissues to produce insulin-like growth factor 1, a stable circulating protein that serves as a practical marker of activity. Clinical studies therefore track IGF-1 concentrations alongside the hormone itself, and they commonly measure body composition with imaging rather than relying on body weight alone. Visceral adipose tissue, the fat surrounding abdominal organs, is quantified by computed tomography in the studies that supported approval. Adverse effects reported in trials include injection-site reactions, joint pain, and increases in blood glucose, which is why monitoring accompanies use.
Questions remain about how much of the observed fat reduction reflects direct GHRH-receptor signaling versus the downstream growth hormone and IGF-1 surge. It is also unclear whether the compound produces meaningful benefit in populations without lipodystrophy, since trials in cognitive impairment did not reach their stated goals. Long-term effects on glucose metabolism and on cardiovascular outcomes are not fully characterized. Published work generally describes effects on surrogate markers rather than on hard clinical endpoints, and independent replication of some findings is limited.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
| Property | Value | Notes |
|---|---|---|
| Receptor target | Growth hormone-releasing hormone receptor | G-protein-coupled receptor expressed on pituitary somatotroph cells |
| Primary signaling route | Cyclic AMP and protein kinase A | Increases intracellular calcium and promotes hormone release |
| Downstream marker | Insulin-like growth factor 1 | Blood concentration used as an integrated activity indicator |
| Study endpoint | Change in visceral adipose tissue | Assessed with computed tomography in trial populations |
| Research status | Investigational outside the approved indication | Trials in cognitive impairment did not meet primary endpoints |
Studies of the compound rely on imaging and laboratory endpoints rather than on symptoms alone. Visceral adipose tissue is usually quantified by computed tomography or magnetic resonance imaging at the level of the abdomen, with waist circumference serving as a cheaper but less specific proxy. Blood work tracks insulin-like growth factor 1, fasting glucose, glycated hemoglobin, and lipid fractions. In the pivotal trials the imaging endpoint fell by roughly fifteen to twenty percent over six months, subcutaneous fat changed little, and the visceral fat returned toward baseline after treatment stopped, a pattern that shapes how clinicians discuss durability.
Whether the drug improves hard clinical outcomes is not settled. No completed trial has shown a reduction in heart attacks or strokes among treated patients, although a dedicated cardiovascular outcomes study has been discussed in the literature. Investigators have also examined hepatic fat in people with HIV and fatty liver disease, cognitive measures in small cohorts, and changes in bone density. Regulatory labeling emphasizes monitoring of insulin-like growth factor 1 because supraphysiologic levels raise questions about tissue growth, and the clinical significance of that signal remains an open question rather than a demonstrated harm.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
Stimulated growth hormone release leads to hepatic production of insulin-like growth factor 1, a key mediator of many growth hormone effects. In clinical studies, tesamorelin increased IGF-1 levels in a dose-dependent manner, although the response varies among individuals. The drug's effect on visceral fat is thought to involve growth hormone-mediated lipolysis and altered adipocyte metabolism. Muscle mass and lean body mass have also been assessed as secondary outcomes, but changes are generally smaller and less consistent than fat reductions.
Pharmacodynamic studies show that tesamorelin reduces visceral adipose tissue more than subcutaneous adipose tissue in the studied population. This selectivity may relate to differences in blood flow and hormone sensitivity between fat depots. Effects on glucose metabolism and insulin sensitivity have been investigated, with some trials reporting modest changes and others showing stability. The precise relationship between growth hormone exposure, IGF-1 levels, and visceral fat loss remains an active area of analysis.
Tesamorelin binds to growth hormone-releasing hormone receptors on somatotroph cells in the anterior pituitary. Receptor activation increases intracellular cyclic AMP and promotes synthesis and secretion of growth hormone. Because the peptide mimics endogenous GHRH, it amplifies the normal pulsatile release of growth hormone rather than providing exogenous growth hormone directly. This upstream action distinguishes tesamorelin from recombinant growth hormone preparations and from growth hormone secretagogues that act at different receptors.
=== Mods === Mod tools for the Source 2 engine and Steam Workshop support for Half-Life: Alyx were released on May 15, 2020. Valve announced plans to release a new Hammer level editor for Source 2, and planned to release a partial Source 2 software development kit for the updated features later, with the focus at launch on shipping and supporting Alyx. In March 2023, fans released the "NoVR" mod, which allows Alyx to be played without a VR headset. This also allows Alyx to run on less powerful devices, such as the Steam Deck. Reviewers found the mod removed immediacy and that mouse-and-keyboard controls could not replicate the dexterity of VR controllers.
=== Electrospray ionization mass spectrometry === Electrospray ionization mass spectrometry is a very versatile technique, consisting in a transfer of the formed complexes from the injected solution to the gas phase by a soft ionization process without strongly perturbing the complex stability. In addition, a small amount of the prepared solution needs to be injected to obtain the speciation spectra. Speciation of several metal ions can be investigated in monophasic solutions at increasing ligand concentration in order to explore all potential complexes. Collision Induced Dissociation (CID) analysis can be also performed to assess the kinetic stability of the formed complexes by discovering the main fragmentation pathway of the ligand. Besides, the protonation effect on the complexation mechanism can be observed by performing analysis on monophasic solutions at increasing nitric acid concentration. Corroboration of the major complexes involved into the extraction process is generally found by performing experiments on biphasic solutions upon extraction tests. Despite versatility of this spectroscopic technique that directly provides information by changing the ligand to metal ratios, its qualitative nature due to instrumental set-up and potential changes in solution chemistry could partially affect species distribution and its ion abundance. For these reasons, corroboration for the speciation results needs to be found by other spectroscopic techniques.
=== Animal nutrition === The Ajinomoto Group started an animal nutrition business in 1965 and subsequently established an international production and supply system for amino acids to be used in animal feed. Ajinomoto developed a lysine formula called AjiPro-L for lactating dairy cows, which allows the lysine to reach the intestine without decomposing in the stomach.
Sources: en.wikipedia.org
Latent autoimmune diabetes in adults (LADA) is an autoimmune disease with gradual or slow destruction of pancreatic beta cells (β-cells). It is a form of type 1 diabetes (T1D) that manifests in adulthood, rather than childhood or adolescence. Due to the adult onset of LADA, as well as the relative preservation of insulin secretion at diagnosis and its slower rate of progression compared to classic T1D, LADA is often misdiagnosed as type 2 diabetes mellitus (T2D) which is a metabolic disorder rather than an autoimmune disease. The concept of LADA was first introduced in 1993. Though sometimes colloquially referred to as "type 1.5 diabetes" due to its sharing some clinical and metabolic characteristics of both T1D and T2D, LADA is strictly defined under the rubric of T1D by the American Diabetes Association (ADA) as an autoimmune form of diabetes. Most individuals with LADA have circulating islet autoantibodies which are indicative of progressive β-cell loss and may help predict the rate of disease progression. Misdiagnosis of LADA can lead to inappropriate treatment, as patients may be managed as having T2D rather than their underlying autoimmune condition.
==== Yeasts ==== Actin's cytoskeleton is key to the processes of endocytosis, cytokinesis, determination of cell polarity and morphogenesis in yeasts. In addition to relying on actin, these processes involve 20 or 30 associated proteins, which all have a high degree of evolutionary conservation, along with many signalling molecules. Together these elements allow a spatially and temporally modulated assembly that defines a cell's response to both internal and external stimuli. Yeasts contain three main elements that are associated with actin: patches, cables, and rings. Despite not being present for long, these structures are subject to a dynamic equilibrium due to continual polymerization and depolymerization. They possess a number of accessory proteins including ADF/cofilin, which has a molecular weight of 16kDa and is coded for by a single gene, called COF1; Aip1, a cofilin cofactor that promotes the disassembly of microfilaments; Srv2/CAP, a process regulator related to adenylate cyclase proteins; a profilin with a molecular weight of approximately 14 kDa that is related/associated with actin monomers; and twinfilin, a 40 kDa protein involved in the organization of patches.
== Advantages and disadvantages == There are several disadvantages to many of these hair removal methods. Hair removal can cause issues: skin inflammation, minor burns, lesions, scarring, ingrown hairs, bumps, and infected hair follicles (folliculitis). Some removal methods are not permanent, can cause medical problems and permanent damage, or have very high costs. Some of these methods are still in the testing phase and have not been clinically proven. One issue that can be considered an advantage or a disadvantage depending upon an individual's viewpoint, is that removing hair has the effect of removing information about the individual's hair growth patterns due to genetic predisposition, illness, androgen levels (such as from pubertal hormonal imbalances or drug side effects), and/or gender status. In the hair follicle, stem cells reside in a discrete microenvironment called the bulge, located at the base of the part of the follicle that is established during morphogenesis but does not degenerate during the hair cycle. The bulge contains multipotent stem cells that can be recruited during wound healing to help repair the epidermis.
=== Esperanto === Since Esperanto allows word compounding, there are no limits on how long a word can theoretically become. An example is the 39-letter word oranĝ-kanton-pafil-limig-aktivul-malamanto, meaning "Orange County gun control activist hater". Such clusters are not considered good style (the 8-word alternative oranĝkantona malamanto de aktivuloj por limigo de pafiloj is more standard), but they are permissible under the rules of Esperanto grammar. Hyphens are optional in Esperanto compounds, so oranĝkantonpafillimigaktivulmalamanto is also technically a valid spelling. Disregarding compounding, conjugation, and affixes, the longest Esperanto word formally recognized by the Akademio de Esperanto is the 15-letter proper noun Konstantinopolo (Constantinople). The next longest recognized words are the following 13-letter words:
Sources: en.wikipedia.org
== Phylogenetics of cytochrome c == Cytochrome c is a highly conserved protein across the spectrum of eukaryotic species, found in plants, animals, fungi, and many unicellular organisms. This, along with its small size (molecular weight about 12,000 daltons), makes it useful in studies of cladistics. Cytochrome c has been studied for the glimpse it gives into evolutionary biology. Cytochrome c has a primary structure consisting of a chain of about 100 amino acids. Many higher-order organisms possess a chain of 104 amino acids. The sequence of cytochrome c in humans is identical to that of chimpanzees (our closest relatives), but differs from that of horses. Cytochrome c has an amino acid sequence that is highly conserved in eukaryotes, varying by only a few residues. In more than thirty species tested in one study, 34 of the 104 amino acids were conserved (identical at their characteristic position). For example, human cytochrome oxidase reacted with wheat cytochrome c, in vitro; which held true for all pairs of species tested. In addition, the redox potential of +0.25 volts is the same in all cytochrome c molecules studied.
The territorial organisation of the Republic of Serbia was regulated by the Law on Territorial Organisation and Local Self-Government, adopted in the Assembly of Serbia on 24 July 1991. Under the Law, the municipalities, cities and settlements make the bases of the territorial organization. Serbia was divided into 195 municipalities and 4 cities, which were the basic units of local autonomy. It had two autonomous provinces: Kosovo and Metohija in the south (with 30 municipalities), which was under the administration of UNMIK after 1999, and Vojvodina in the north (with 46 municipalities and 1 city). The territory between Kosovo and Vojvodina was called Central Serbia. Central Serbia was not an administrative division on its own and had no regional government of its own. In addition, there were four cities: Belgrade, Niš, Novi Sad and Kragujevac, each having an assembly and budget of its own. The cities comprised several municipalities, divided into "urban" (in the city proper) and "other" (suburban). Competences of cities and their municipalities were divided. Municipalities were gathered into districts, which are regional centres of state authority, but have no assemblies of their own; they present purely administrative divisions, and host various state institutions such as funds, office branches and courts. The Republic of Serbia was then and is still today divided into 29 districts (17 in Central Serbia, 7 in Vojvodina and 5 in Kosovo, which are now defunct), while the city of Belgrade presents a district of its own.
The middle layer of the heart wall is the myocardium, which is the cardiac muscle—a layer of involuntary striated muscle tissue surrounded by a framework of collagen. The cardiac muscle pattern is elegant and complex, as the muscle cells swirl and spiral around the chambers of the heart, with the outer muscles forming a figure 8 pattern around the atria and around the bases of the great vessels and the inner muscles, forming a figure 8 around the two ventricles and proceeding toward the apex. This complex swirling pattern allows the heart to pump blood more effectively. There are two types of cells in cardiac muscle: muscle cells which have the ability to contract easily, and pacemaker cells of the conducting system. The muscle cells make up the bulk (99%) of cells in the atria and ventricles. These contractile cells are connected by intercalated discs which allow a rapid response to impulses of action potential from the pacemaker cells. The intercalated discs allow the cells to act as a syncytium and enable the contractions that pump blood through the heart and into the major arteries. The pacemaker cells make up 1% of cells and form the conduction system of the heart. They are generally much smaller than the contractile cells and have few myofibrils which gives them limited contractibility. Their function is similar in many respects to neurons. Cardiac muscle tissue has autorhythmicity, the unique ability to initiate a cardiac action potential at a fixed rate—spreading the impulse rapidly from cell to cell to trigger the contraction of the entire heart.
Sources: en.wikipedia.org
It acts upstream at the pituitary receptor and depends on functioning somatotroph cells to produce any effect. Growth hormone injections bypass that step and deliver the hormone directly. The pharmacokinetic profiles and the resulting feedback on the body's own secretion therefore differ.
Insulin-like growth factor 1 is a downstream product of growth hormone action and changes more slowly than the hormone itself. Its blood concentration is used as an integrated indicator of whether the pathway has been stimulated. Interpretation requires attention to nutrition, illness, and other factors that shift IGF-1 independently.
No. The approved indication concerns excess visceral abdominal fat in adults with HIV infection and lipodystrophy, a specific clinical population. It is not cleared for general weight reduction or for cosmetic use. Studies in other groups remain investigational.
It is a laboratory-made peptide of forty-four amino acids whose sequence matches human growth hormone-releasing hormone, with a modified amino terminus. The modification is a short unsaturated fatty acid chain attached to the first residue. This change slows enzymatic breakdown and lengthens the time the peptide stays active in circulation.